Last reviewed · How we verify

angiotensin blockade — Competitive Intelligence Brief

angiotensin blockade (angiotensin blockade) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin receptor blocker (ARB) or ACE inhibitor. Area: Cardiovascular.

marketed Angiotensin receptor blocker (ARB) or ACE inhibitor Angiotensin II type 1 receptor (AT1R) or Angiotensin-converting enzyme (ACE) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

angiotensin blockade (angiotensin blockade) — The University of Hong Kong. Angiotensin blockade inhibits the renin-angiotensin-aldosterone system (RAAS) to reduce vasoconstriction and lower blood pressure.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
angiotensin blockade TARGET angiotensin blockade The University of Hong Kong marketed Angiotensin receptor blocker (ARB) or ACE inhibitor Angiotensin II type 1 receptor (AT1R) or Angiotensin-converting enzyme (ACE)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiotensin receptor blocker (ARB) or ACE inhibitor class)

  1. The University of Hong Kong · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). angiotensin blockade — Competitive Intelligence Brief. https://druglandscape.com/ci/angiotensin-blockade. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: